Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Free Cash Flow (2020 - 2025)

HCW Biologics (HCWB) has disclosed Free Cash Flow for 6 consecutive years, with -$3.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Free Cash Flow rose 31.44% year-over-year to -$3.2 million, compared with a TTM value of -$11.2 million through Sep 2025, up 47.33%, and an annual FY2024 reading of -$14.5 million, up 49.54% over the prior year.
  • Free Cash Flow was -$3.2 million for Q3 2025 at HCW Biologics, up from -$3.3 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $6.4 million in Q4 2022 and bottomed at -$12.5 million in Q3 2022.
  • Average Free Cash Flow over 5 years is -$3.9 million, with a median of -$3.5 million recorded in 2025.
  • The sharpest move saw Free Cash Flow skyrocketed 288.93% in 2022, then tumbled 310.62% in 2023.
  • Year by year, Free Cash Flow stood at -$3.4 million in 2021, then surged by 288.93% to $6.4 million in 2022, then crashed by 224.69% to -$8.0 million in 2023, then soared by 85.18% to -$1.2 million in 2024, then tumbled by 173.23% to -$3.2 million in 2025.
  • Business Quant data shows Free Cash Flow for HCWB at -$3.2 million in Q3 2025, -$3.3 million in Q2 2025, and -$3.5 million in Q1 2025.